Renal Cell Carcinoma Clinical Trials

Birmingham : University of Alabama at Birmingham

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Muscle Shoals : Northwest Alabama Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Scottsdale : Research Site

AMG 172 First in Human Study in Patients With Kidney Cancer

Scottsdale :

AMG 172 First in Human Study in Patients With Kidney Cancer

Hot Springs : Genesis Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Burbank : Providence Health System: Roy and Patricia Disney Family Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Corona : Compassionate Cancer Care Medical Group Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Corona : Compassionate Cancer Care Medical Group, Inc. Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Duarte : City of Hope Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Duarte : City Of Hope Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

View More »

Fountain Valley : Robert A. Moss, M.D., FACP, Inc. Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Fresno : California Cancer Associates for Research and Excellence Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Greenbrae : Marin Specialty Care Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Los Angeles : Good Samaritan Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Los Angeles : UCLA Med - Hematology & Oncology Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Los Angeles : Samuel Oschin Cancer Center at Cedars-Sinai Medical Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Riverside : Compassionate Cancer Care Medical Group Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

San Francisco : Ucsf Helen Diller Family Comprehensive Cancer Center Updated

Phase I Biomarker Study (BMS-936558)

Stanford : Stanford Cancer Center

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Whittier : American Institute of Research Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Denver : The Urology Center of Colorado

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

View More »

Denver : Rocky Mountain Cancer Centers - Midtown

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Denver : Centura Health Research Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Denver : The Urology Center of Colorado Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Golden : Western Oncology & Hematology Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Parker : Advanced Urology, P.C. Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

New Haven : Yale University School Of Medicine Updated

Phase I Biomarker Study (BMS-936558)

Brooksville : Cancer Care Centers of Florida: Brooksville Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Ft. Lauderdale : Broward Oncology Associates Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Gainesville : University of Florida, Shands Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Jacksonville : Cancer Specialists of North Florida Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Miami : Advanced Pharma CR, LLC Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

View More »

Miami Beach : Research Site

A Phase 1 Study to Evaluate MEDI4736

New Port Richey : Cancer Care Centers of Florida Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Ocala : Ocala Cancer Institute Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Rockledge : Cancer Care Centers of Brevard Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Tampa : Research Site

A Phase 1 Study to Evaluate MEDI4736

Tampa : H. Lee Moffitt Cancer Center & Research Institute Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Tampa : H Lee Moffitt Cancer Center Updated

Phase I Biomarker Study (BMS-936558)

Savannah : Memorial University Medical Center

CALBG 90802: Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors

View More »

Athens : Northeast Georgia Cancer Care, LLC Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Atlanta : Emory Univeristy Hospital Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Augusta : Research Site

A Phase 1 Study to Evaluate MEDI4736

Dublin : Dublin Hematology & Oncology Care Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Post Falls : Kootenai Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Berwyn : Vanguard Health Chicago Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Chicago : Northwestern University, Robert H. Lurie Comprehensive Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Chicago : University Of Chicago Medical Center Updated

Phase I Biomarker Study (BMS-936558)

Maywood : Loyola University of Chicago, Cardinal Bernardin Cancer Center

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Skokie : Edward H. Kaplan, M.D., & Associates Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

View More »

Skokie : Edward H. Kaplan and Associates Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Springfield : Southern Illinois University - Simmons Cancer Institute Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Evansville : Deaconess Clinic Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Fort Wayne : Fort Wayne Oncology & Hematology, Inc Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Goshen : IU Health Goshen Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Greenwood : Urology of Indiana Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Indianapolis : Indiana University Melvin and Bren Simon Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

View More »

Indianapolis : Community Regional Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Indianapolis : IU Health Central Indiana Cancer Centers Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Indianapolis : Indiana University Melvin and Bren Simon Cancer Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Indianapolis : Franciscan St. Francis Health - Franciscan Physician Network Oncology and Hematology Specialists Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Lafayette : Horizon Oncology Research Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Muncie : IU Health at Ball Memorial Hospital Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Munster : Monroe Medical Associates Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Newburgh : Oncology Hematology Associates of SW Indiana Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

South Bend : Northern Indiana Cancer Research Consortium Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Iowa City : University of Iowa Hospital and Clinics Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Sioux City : Siouxland Hematology Oncology Associates, LLP, Nylen Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Wichita : Cancer Center of Kansas Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Wichita : Cancer Center of Kansas

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Hazard : Kentucky Cancer Clinic Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Paducah : Purchase Cancer Group Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Baton Rouge : Medical Oncology LLC Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Metairie : Metairie Oncologists Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Metairie : East Jefferson General Hospital Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Baltimore : Sidney Kimmel Comprehensive Cancer Center at John Hopkins Hospital

A Safety Study of LBH589 (Panobinostat) and RAD001 (Everolimus) to Stabilize Kidney Cancer

Baltimore : Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Baltimore : The Bunting-Blaustein Cancer Research Building Updated

Phase I Biomarker Study (BMS-936558)

Boston : Dana-Farber Cancer Institute

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Boston : Beth Israel Deaconess Medical Center

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Boston : Beth Israel Deaconess Medical Center

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Boston : Dana-Farber Cancer Institute

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Boston : Beth Israel Deaconess Medical Center

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

View More »

Boston : Tufts Medical Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Boston : Dana-Farber Cancer Institute

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Boston : Beth Israel Deaconess Medical Center`

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Boston : Massachusetts General Hospital

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Boston : Beth Israel Deaconess Medical Center Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Boston : Dana Farber Cancer Inst Updated

Phase I Biomarker Study (BMS-936558)

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Ann Arbor : St. Joseph Mercy Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Ann Arbor : University Of Michigan Medical Center Updated

Phase I Biomarker Study (BMS-936558)

Detroit : Karmanos Cancer Institute / Wayne State University

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Detroit : Henry Ford Hospital

Association Between Hepatitis C Infection and Renal Cell Carcinoma

Detroit : Karmanos Cancer Institute - Wayne State University School of Medicine Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

View More »

Grand Rapids : Cancer and Hematology Centers of Western Michigan Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Grand Rapids : Cancer and Hematology Clinics of Western Michigan - Spectrum Health Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Wyoming : Metro Health Cancer Care Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Rochester : Mayo Clinic Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

St. Louis : Research Site

AMG 172 First in Human Study in Patients With Kidney Cancer

St. Louis : Washington University School of Medicine Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Great Falls : Sletten Cancer Specialists Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Omaha : Methodist Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Omaha : Missouri Valley Cancer Consortium

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Las Vegas :

Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

Lebanon : Dartmouth-Hitchcock Medical Center Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Lebanon : Dartmouth Hitchcock Medical Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Manchester : Dartmouth-Hitchcock Medical Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Elizabeth : Trinitas Regional Medical Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Hackensack : John Theurer Cancer Center At Hackensack UMC Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Somerville : Somerset Hematology Oncology Associates Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Albuquerque : Presbyterian Medical Group Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Albuquerque : University of New Mexico Cancer Care Alliance Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Manhasset : Biomedical Research Alliance of New York, LLC

Study for high risk recurrence of renal cell carcinoma after surgical treatment

View More »

Albany : New York Oncology Hematology, PC Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Albany : Albany Medical Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Buffalo : Roswell Park Cancer Institute

A Safety Study of LBH589 (Panobinostat) and RAD001 (Everolimus) to Stabilize Kidney Cancer

Buffalo : Roswell Park Cancer Institute Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

East Syracuse : Hematology Oncology Associates of CNY Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Lake Success : NYU Langone Arena Oncology Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

New York : Research Site

A Phase 1 Study to Evaluate MEDI4736

New York : Memorial Sloan Kettering Cancer Center

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

New York : Tisch Cancer Institute at Mount Sinai Medical Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

New York : Memorial Sloan Kettering Cancer Center

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

New York : Weill Cornell Medical College

Neoadjuvant Pazopanib in Renal Cell Carcinoma

New York : Memorial Sloan Kettering Cancer Center Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

New York : Mount Sinai School of Medicine - Medical Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Nyack : Hematology Oncology Associates of Rockland Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Syracuse : Associated Medical Professionals of New York Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Syracuse : SUNY Upstate Medical University Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Chapel Hill : North Carolina Cancer Hospital (UNC)

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Charlotte : Carolinas HealthCare System

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Charlotte : Levine Cancer Institute Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Durham : Duke University Medical Center

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

Durham : Duke University Medical Center

Neoadjuvant Pazopanib in Renal Cell Carcinoma

View More »

Durham : Duke University Medical Center Updated

Phase I Biomarker Study (BMS-936558)

Pinehurst : First Health of the Carolinas Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Cincinnati : TriState Urologic Services PSC Inc. The Urology Group Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Cleveland : Cleveland Clinic, Taussig Cancer Institute

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Cleveland : Cleveland Clinic Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Middletown : Signal Point Clinical Research Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Middletown : Signal Point Clinical Research Center, LLC Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

View More »

Toledo : Mercy Cancer Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Wooster : Lawrence M. Stallings, M.D. Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Oklahoma City : Mercy Physicians Of Oklahoma Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Oklahoma City : University of Oklahoma Health Sciences Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Portland : Providence Portland Med Ctr Updated

Phase I Biomarker Study (BMS-936558)

Springfield : Willamette Valley Cancer Institute Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Allentown : Lehigh Valley Hospital Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Bethlehem : St. Luke's Hospital - Bethlehem Campus Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Danville : Geisinger Medical Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Gettysburg : Gettysburg Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Lancaster : Urological Associates of Lancaster Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

View More »

Philadelphia : University of Pennsylvania, Abramson Cancer Center

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Philadelphia : Fox Chase Cancer Center

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Philadelphia : Fox Chase Cancer Center Updated

Phase I Biomarker Study (BMS-936558)

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Pittsburgh : Allegheny Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Pittsburgh : University of Pittsburgh Medical Center

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Pittsburgh : Upmc Cancer Pavilion Updated

Phase I Biomarker Study (BMS-936558)

Rockledge : Fox Chase Cancer Center Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

State College : Mount Nittany Medical Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

West Reading : Berks Hematology Oncology Associates Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Cranston : Hematology and Oncology Associates of Rhode Island Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Providence : Miriam Hospital, The

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Charleston : Medical University of South Carolina

A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

Charleston : MUSC Hollings Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Charleston : Medical University of South Carolina (MUSC)

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Charleston : Medical University of South Carolina (MUSC) Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Greenville : Greenville Hospital System - Cancer Centers of the Carolinas Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

View More »

Hilton Head Island : South Carolina Cancer Specialists Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Myrtle Beach : Carolina Urologic Research Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Germantown : The Jones Clinic, PC Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Nashville : Vanderbilt Univeristy Medical Center

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Nashville : Tennessee Oncology, Pllc Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Nashville : Vanderbilt University School of Medicine Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Austin : Texas Oncology: Austin North Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Bedford : Texas Oncology: Bedford Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Dallas : Texas Oncology, PA Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Fort Worth : Texas Oncology: Fort Worth Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Galveston : University of Texas Medical Branch - Galveston Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

View More »

Houston : Texas Oncology: Houston Memorial City Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Houston : Houston Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Houston : The University of Texas MD Anderson Cancer Center Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Houston : M.D. Anderson Cancer Center Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Lubbock : Joe Arrington Cancer Research and Treatment Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

San Antonio : CTRC at The UT Health Science Center at San Antonio Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Salt Lake City : University of Utah Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Lynchburg : Lynchburg Hematology Oncology Clinic, Inc. Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Norfolk : Urology of Virginia Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Bremerton : Harrison HealthPartners Bremerton Hematology & Oncology Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Kirkland : Cascade Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Seattle : Seattle Cancer Care Alliance / University of Washington

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Seattle : University of Washington, Seattle Cancer Care Alliance Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Seattle : Group Health Medical Centers Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

View More »

Spokane : Rockwood Clinic Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Madison : University Of Wisconsin Carbone Cancer Center Updated

Phase I Biomarker Study (BMS-936558)

Milwaukee : University of Wisconsin, Clinical Cancer Center Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Milwaukee : Aurora Health Care Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Alger : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Oran : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Adelaide : Royal Adelaide Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Camperdown : Royal Prince Alfred Hospital: Sydney Cancer Centre Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Frankston : Peninsula Oncology Centre Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Greenslopes : Gallipoli Medical Research Foundation: Greenslopes Private Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Heidelberg : Austin Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

View More »

Herston : Royal Brisbane & Women's Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Kurralta Park : Ashford Cancer Centre Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Launceston : Gallipoli Medical Research Foundation: Launceston General Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Melbourne : Alfred Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Perth : Royal Perth Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Randwick : Prince of Wales Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Wahroonga : Sydney Adventist Hospital Ltd. Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Wolloongabba : Princess Alexandra Hospital Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Calgary : Local Institution Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Edmonton : Local Institution Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Montreal : Jewish General Hospital Updated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Ottawa : Local Institution Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Toronto : University Health Network, Princess Margaret Hospital

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

View More »

Toronto : Toronto General Hospital

Efficacy of Ultrasound Contrast Agent to Assess Renal Masses

Toronto : Local Institution Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Vancouver : Local Institution Updated

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Beijing : Beijing Cancer Hospital

Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Chengdu : West China Hospital

Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Guangzhou : Sun Yat-sen university cancer center

Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Shenyang : Shenyang general hospital of Shenyang military command

Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Xi'an : Xijing Hospital

Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Villejuif : Research Site

AMG 172 First in Human Study in Patients With Kidney Cancer

Berlin : Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30

Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

Freiburg : iOMEDICO

Tumor Registry of Advanced Renal Cell Carcinoma

Heidelberg : Research Site

AMG 172 First in Human Study in Patients With Kidney Cancer

Indore : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Pune : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Cork : Cork University Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Dublin : The Adelaide & Meath Hospital Dublin incorporating the National Children's Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Dublin : Mater Private Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Dublin : Beaumont Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Dublin : Mater Misericordiae University Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

View More »

Galway : Galway University Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Limerick : Mid-Western Regional Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Waterford : Waterford Regional Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Fukuoka-shi : Kyusyu University Hospital

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Osakasayama : Kinki University Hospital Updated

Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)

Amman : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Seoul : Seou National University Hospital

A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

Beirut : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Kazan : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Moscow : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Samara : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Ulyanovsk : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Riyadh : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Singapore : National Cancer Centre Singapore Updated

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Cape Town : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Durban : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Parktown : Novartis Investigative Site

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma

Stockholm : Karolinska University Hospital

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study

Many Locations : Updated

Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

Cambridge : Cambridge University Hospitals NHS Foundation Trust Updated

HYPAZ: Hypertension Induced by Pazopanib

London :

Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy